Get the Stockscreener App
67.06
0.56%
-0.38
Structure Therapeutics Inc Adr stock is traded at $67.06, with a volume of 1.50M.
It is down -0.56% in the last 24 hours and up +86.69% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$67.44
Open:
$68.61
24h Volume:
1.50M
Relative Volume:
1.06
Market Cap:
$4.07B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-30.21
EPS:
-2.22
Net Cash Flow:
$-105.32M
1W Performance:
+94.04%
1M Performance:
+86.69%
6M Performance:
+201.80%
1Y Performance:
+111.48%
1-Day Range:
$65.81
$68.91
1-Week Range:
$44.74
$94.90
52-Week Range:
$13.22
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(650) 457-1978
Address
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
67.06 | 4.09B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Bellevue Group AG Acquires 126,812 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Birchview Capital LP Buys Shares of 36,000 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Raised to Hold at Wall Street Zen - Defense World
Structure Therapeutics Inc. (GPCR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Structure Therapeutics (NASDAQ:GPCR) Price Target Raised to $120.00 - MarketBeat
Structure Therapeutics stock price target raised to $120 by Citizens - Investing.com India
Federated Hermes Inc. Decreases Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Structure Therapeutics closes $747.5 million public offering - Investing.com
Structure Therapeutics Announces $650 Million Public Offering - TipRanks
Structure Therapeutics’ Leap: What’s Sparking the Surge? - StocksToTrade
Structure Therapeutics Shares Surge on Promising Drug Results - TipRanks
Structure Therapeutics Inc. (GPCR) Stock: Skyrockets After Positive Obesity Trial Result - Menafn
Structure Therapeutics prices upsized $650 million public offering By Investing.com - Investing.com South Africa
Structure Therapeutics prices upsized $650 million public offering - Investing.com
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants - GlobeNewswire Inc.
Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial - Finviz
Structure Therapeutics (NASDAQ:GPCR) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Discipline and Rules-Based Execution in GPCR Response - news.stocktradersdaily.com
Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook - ts2.tech
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron - Yahoo Finance
This trade activity should not be overlooked: Structure Therapeutics Inc ADR (GPCR) - setenews.com
Structure Therapeutics stock price target raised to $130 by BMO Capital - Investing.com
Structure Therapeutics stock price target raised to $99 at Clear Street - Investing.com
Biggest Stock Gainers Today in the US (Dec. 9, 2025): Wave Life Sciences, Structure Therapeutics, Confluent and More - ts2.tech
Structure Therapeutics Stock Jumps on Trial Results for Weight-Loss Pill - The Wall Street Journal
Why Structure Therapeutics Stock Doubled and Then Some on Monday - The Globe and Mail
Structure Therapeutics stock hits 52-week high at 45.05 USD By Investing.com - Investing.com Canada
Structure Therapeutics Unveils Major Data Release Driving Market Buzz - StocksToTrade
Structure Therapeutics stock price target raised to $90 by Stifel - Investing.com
Mid Cap Stocks To Watch TodayDecember 8th - MarketBeat
Structure Therapeutics stock falls after $500 million share offering - Investing.com India
Structure Therapeutics launches $500 million public offering By Investing.com - Investing.com South Africa
Structure Therapeutics (NASDAQ: GPCR) plans $500M ADS sale with $75M option - Stock Titan
2 companies poised to capitalize on the rise of GLP-1 drugs - Morningstar Australia
Structure Therapeutics’ Potential Breakthrough: Market Awaits Data - StocksToTrade
Pharmaceutical Stocks To Follow TodayDecember 8th - MarketBeat
Medical Stocks To Watch TodayDecember 8th - MarketBeat
Promising Potential of Structure Therapeutics’ Aleniglipron: A Buy Rating Based on Transformative Efficacy and Strategic Innovation - TipRanks
Positive Outlook for Structure Therapeutics: Aleniglipron Shows Promising Results in Obesity Treatment - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Hits New 1-Year HighStill a Buy? - MarketBeat
Structure Phase 2 data for aleniglipron look ‘competitive,’ says Morgan Stanley - TipRanks
Structure Therapeutics posts mid-stage weight-loss pill data in line with Eli Lilly rival - Sherwood News
Structure Therapeutics stock hits 52-week high at 45.05 USD - Investing.com
Structure Therapeutics Announces Positive Clinical Trial Results - TipRanks
Structure Therapeutics stock soars after strong weight loss data for oral drug - Investing.com UK
Biotech Soars On Potential 'Best-In-Class' Obesity Drug - Investor's Business Daily
Structure Therapeutics’ Stocks Surge on Promising Drug Data - TipRanks
GPCR: Aleniglipron achieved up to 15.3% weight loss at 36 weeks with strong safety and no plateau - TradingView
GPCR: Aleniglipron showed up to 15.3% weight loss at 36 weeks with strong safety and tolerability - TradingView
Structure Therapeutics (NASDAQ: GPCR) oral GLP-1 cuts weight up to 15.3% in Phase 2 data - Stock Titan
Why Structure Therapeutics (GPCR) Is Up 102.4% After Positive Phase 2 Data For Oral GLP-1 Aleniglipron - Sahm
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):